Literature DB >> 31642874

Apolipoprotein B Particles and Cardiovascular Disease: A Narrative Review.

Allan D Sniderman1, George Thanassoulis1, Tamara Glavinovic2, Ann Marie Navar3,4, Michael Pencina5,6, Alberico Catapano7, Brian A Ference8,9,10.   

Abstract

Importance: The conventional model of atherosclerosis presumes that the mass of cholesterol within very low-density lipoprotein particles, low-density lipoprotein particles, chylomicron, and lipoprotein (a) particles in plasma is the principal determinant of the mass of cholesterol that will be deposited within the arterial wall and will drive atherogenesis. However, each of these particles contains one molecule of apolipoprotein B (apoB) and there is now substantial evidence that apoB more accurately measures the atherogenic risk owing to the apoB lipoproteins than does low-density lipoprotein cholesterol or non-high-density lipoprotein cholesterol. Observations: Cholesterol can only enter the arterial wall within apoB particles. However, the mass of cholesterol per apoB particle is variable. Therefore, the mass of cholesterol that will be deposited within the arterial wall is determined by the number of apoB particles that are trapped within the arterial wall. The number of apoB particles that enter the arterial wall is determined primarily by the number of apoB particles within the arterial lumen. However, once within the arterial wall, smaller cholesterol-depleted apoB particles have a greater tendency to be trapped than larger cholesterol-enriched apoB particles because they bind more avidly to the glycosaminoglycans within the subintimal space of the arterial wall. Thus, a cholesterol-enriched particle would deposit more cholesterol than a cholesterol-depleted apoB particle whereas more, smaller apoB particles that enter the arterial wall will be trapped than larger apoB particles. The net result is, with the exceptions of the abnormal chylomicron remnants in type III hyperlipoproteinemia and lipoprotein (a), all apoB particles are equally atherogenic. Conclusions and Relevance: Apolipoprotein B unifies, amplifies, and simplifies the information from the conventional lipid markers as to the atherogenic risk attributable to the apoB lipoproteins.

Entities:  

Year:  2019        PMID: 31642874     DOI: 10.1001/jamacardio.2019.3780

Source DB:  PubMed          Journal:  JAMA Cardiol            Impact factor:   14.676


  69 in total

Review 1.  Beyond Statins and PCSK9 Inhibitors: Updates in Management of Familial and Refractory Hypercholesterolemias.

Authors:  Fabiana Rached; Raul D Santos
Journal:  Curr Cardiol Rep       Date:  2021-06-03       Impact factor: 2.931

2.  ANGPTL3, PCSK9, and statin therapy drive remarkable reductions in hyperlipidemia and atherosclerosis in a mouse model.

Authors:  Eva Hurt-Camejo
Journal:  J Lipid Res       Date:  2020-01-24       Impact factor: 5.922

Review 3.  Clinical Management of Hypertriglyceridemia in the Prevention of Cardiovascular Disease and Pancreatitis.

Authors:  Patricia Hernandez; Neena Passi; Taher Modarressi; Vivek Kulkarni; Meshal Soni; Fran Burke; Archna Bajaj; Daniel Soffer
Journal:  Curr Atheroscler Rep       Date:  2021-09-13       Impact factor: 5.113

4.  Cholesterol Metabolism in Chronic Kidney Disease: Physiology, Pathologic Mechanisms, and Treatment.

Authors:  Xiaoyue Pan
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

5.  Peptides as Therapeutic Agents for Atherosclerosis.

Authors:  C Roger White; Mayakonda Palgunachari; Paul Wolkowicz; G M Anantharamaiah
Journal:  Methods Mol Biol       Date:  2022

6.  Plasma Apolipoproteins A1/B and OxLDL Levels in Patients with Covid-19 As Possible Markers of the Disease.

Authors:  V V Pushkarev; L K Sokolova; S A Chervyakova; Yu B Belchina; O I Kovzun; V M Pushkarev; M D Tronko
Journal:  Cytol Genet       Date:  2021-11-29       Impact factor: 0.579

7.  Association of Apolipoprotein B-Containing Lipoproteins and Risk of Myocardial Infarction in Individuals With and Without Atherosclerosis: Distinguishing Between Particle Concentration, Type, and Content.

Authors:  Nicholas A Marston; Robert P Giugliano; Giorgio E M Melloni; Jeong-Gun Park; Valerie Morrill; Michael A Blazing; Brian Ference; Evan Stein; Erik S Stroes; Eugene Braunwald; Patrick T Ellinor; Steven A Lubitz; Christian T Ruff; Marc S Sabatine
Journal:  JAMA Cardiol       Date:  2022-03-01       Impact factor: 14.676

8.  Human Insulin Growth Factor 2 mRNA Binding Protein 2 Increases MicroRNA 33a/b Inhibition of Liver ABCA1 Expression and Alters Low-Density Apolipoprotein Levels in Mice.

Authors:  Muhua Yang; Christina Gallo-Ebert; Michael Hayward; Weidong Liu; Virginia McDonough; Joseph T Nickels
Journal:  Mol Cell Biol       Date:  2020-07-29       Impact factor: 4.272

9.  High-throughput multivariable Mendelian randomization analysis prioritizes apolipoprotein B as key lipid risk factor for coronary artery disease.

Authors:  Verena Zuber; Dipender Gill; Mika Ala-Korpela; Claudia Langenberg; Adam Butterworth; Leonardo Bottolo; Stephen Burgess
Journal:  Int J Epidemiol       Date:  2021-07-09       Impact factor: 7.196

10.  NMU DNA methylation in blood is associated with metabolic and inflammatory indices: results from the Moli-sani study.

Authors:  Annalisa Marotta; Fabrizia Noro; Roberta Parisi; Alessandro Gialluisi; Alfonsina Tirozzi; Amalia De Curtis; Simona Costanzo; Augusto Di Castelnuovo; Chiara Cerletti; Maria Benedetta Donati; Giovanni de Gaetano; Licia Iacoviello; Benedetta Izzi; Francesco Gianfagna
Journal:  Epigenetics       Date:  2021-01-04       Impact factor: 4.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.